Please note: The information displayed on this page might be outdated.
Eureka Therapeutics: Developer of an antibody drug discovery platform designed to offer therapeutic antibody treatments. The company's platform is focused on improving the safety profile of T cell therapies and developing novel T cell therapies for the treatment of solid tumors, enabling clients to avail a pipeline of novel cancer therapeutics targeting intracellular oncogenes as well as cell-surface antigens.
US - Pacific
Company Participants at Winter Private Company Showcase
Eureka Therapeutics, CEO
Dr. Cheng Liu is our founder and CEO. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a PhD in Molecular Cell Biology from the University of California, Berkeley.
Eureka Therapeutics, SVP, Corporate Development
Mr. Li has served as Senior Vice President of Corporate Development at Eureka therapeutics since February 2019. He is responsible for business and corporate development. Dr. Li has over twenty years of experience in the biopharmaceutical industry and in finance on Wall Street. Prior to Eureka, he served as CFO Ascentage Pharma Group, a biotech company. From 2010 to 2017, Dr. Li worked in Strategic Marketing at Bayer Pharmaceuticals, responsible for Strategy and Portfolio Management and Commercial Development. Before Bayer, Dr. Li worked for Morgan Stanley, Suntrust Robinson Humphrey and Stanford Financial Group. Dr. Li holds a PhD degree in Pharmacology from Boston University School of Medicine and an MBA. degree in Finance from University of California at Los Angeles.